CVS Health today announced that the U.S. Department of Justice (DOJ) will allow its proposed acquisition of Aetna to proceed. Read the CVS Health press release.
Under the DOJ consent decree, closing of the CVS Health-Aetna transaction may proceed prior to the effective date of Aetna’s previously announced divestiture of its entire standalone Medicare Part D business to a subsidiary of WellCare Health Plans, Inc.
Aetna’s agreement with WellCare covers both Individual and Group standalone Part D members. Aetna will continue to administer and provide service and support for the impacted plans throughout the 2019 benefit year, and members will see no change in 2019 benefits, networks, formularies or premiums as a result of the sale to WellCare.
It’s important to note that all other Aetna plans and products, including Aetna Individual Medicare Advantage (MA), integrated Medicare Advantage with Part D (MAPD), and standalone (MA-only) Group Medicare Advantage, Medicare Supplement, Ancillary, and Commercial plans and products, are not impacted by the sale to WellCare.
Members are encouraged to call the number on their Aetna ID card if they have questions or need additional information.